^
Association details:
| Biomarker: | LAG3 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.
Published date:
05/25/2023
Excerpt:
...72 metastatic NSCLC patients treated with pembrolizumab alone...LAG3 high patients in RC showed significantly higher OS (median OS = not reached; p = 0.016) and PFS (median PFS = not reached; p < 0.0001) compared the LAG3 low patients (median OS = 12 months; median PFS = 6.5 months). LAG3 high cases had significantly (ORR = 65%, p = 0.005) improved ICI response compared to LAG3 low cases (ORR = 35%)....Additionally, LAG3 is strongly associated with proliferation and significantly improved outcomes for patients with NSCLC, treated with pembrolizumab alone.
DOI:
10.1200/JCO.2023.41.16_suppl.e21113
